- Email: [email protected]
5026646 Bovine monoclonal antibodies to bovine herpesvirus I form sequential fusion heterohybridomas
vi
New Patents
stabilizing vaccines adjuvanted with such dimethyl dioctadecyl ammonium bromide.
5026557 ADJUVANT
COMPOSITION
Leonard Estis, Phillip Livingston assigned to The Liposome Company Inc An adjuvant composition comprising a small liposome with incubation associated immunopotentiator such as Lipid A, said composition with incubation associated antigen, and method of preparation and use.
lymphocytes with an immortal cell line, selecting for secretial hybrids, and sequentially re-fusing such hybrids with fresh bovine lymphocytes. Three such heterohybridomas which secrete neutralizing antibody to BHV-I have been obtained in this manner and have been deposited in the ATCC as Accession Nos. HB 9907, HB 9908. and HB 9909. The neutralizing antibodies are useful in immunological research, pathological diagnosis, and therapeutic disease control. Specifically, they have utility as serologic control reagents in assays, and as primary reagents in anti-species, anti-isotype, and anti-idiotypic antibody production.
5026687 5026636 METHODS AND COMPOSITIONS FOR PRODUCTION OF MYCOPLASMAL ADHESINS Joel Baseman, C J Su, S Dallo assigned to The University of Texas Board of Regents The molecular cloning and nucleotide sequence of the complete structural gene encoding Mycoplasma pneumoniae PI cytadhesin and the amino acid sequence of the PI protein is described. The present invention provides recombinant DNA clones encoding the complete PI protein as well as clones expressing PI polypeptides with cytadhesin epitopes. The substantially purified nucleic acid molecular recombinant vectors, recombinant cells, and recombinant polypeptides of the present invention are useful as hybridization probes and immunodiagnostic reagents and may be used to prepare anti-mycoplasmal vaccines.
5026646 BOVINE M O N O C L O N A L ANTIBODIES TO BOVINE HERPESVIRUS ! FROM SEQUENTIAL FUSION HETEROHYBRIDOMAS Randall L Levings, lone R Stoll assigned to The United States of America as represented by the Secretary of Agriculture Stable heterohybridomas which secrete monoclonal antibodies to bovine herpesvirus-1 (BHVI) are obtained by fusing primed bovine
TREATMENT OF HUMAN RETROVIRAL INFECTIONS WITH 2',3'-DIDEOXYINOSINE ALONE A N D IN C O M B I N A T I O N W I T H OTHER ANTIVIRAL COMPOUNDS Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder assigned to The United States of America as represented by the Department of Health and Human Services A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeliciency virus (HIV) infection, with 2'.3"dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2". 3"dideoxyinosine to minimize certain side effects.
5028421 M E T H O D OF TREATING BIRDS Tommy L Fredericksen, James P Thaxton assigned to Embrex Inc A method of treating birds by administering birds in ovo a T-cell growth factor comprising avian IL-2 is disclosed. The method is preferably carried out on chickens with 30K chicken IL-2 on about the eighteenth day of incubation. The method may be employed to increase the weight of treated birds after hatch. A vaccine may optionally be administered concurrently with the avian 1L-2.
New Patents
stabilizing vaccines adjuvanted with such dimethyl dioctadecyl ammonium bromide.
5026557 ADJUVANT
COMPOSITION
Leonard Estis, Phillip Livingston assigned to The Liposome Company Inc An adjuvant composition comprising a small liposome with incubation associated immunopotentiator such as Lipid A, said composition with incubation associated antigen, and method of preparation and use.
lymphocytes with an immortal cell line, selecting for secretial hybrids, and sequentially re-fusing such hybrids with fresh bovine lymphocytes. Three such heterohybridomas which secrete neutralizing antibody to BHV-I have been obtained in this manner and have been deposited in the ATCC as Accession Nos. HB 9907, HB 9908. and HB 9909. The neutralizing antibodies are useful in immunological research, pathological diagnosis, and therapeutic disease control. Specifically, they have utility as serologic control reagents in assays, and as primary reagents in anti-species, anti-isotype, and anti-idiotypic antibody production.
5026687 5026636 METHODS AND COMPOSITIONS FOR PRODUCTION OF MYCOPLASMAL ADHESINS Joel Baseman, C J Su, S Dallo assigned to The University of Texas Board of Regents The molecular cloning and nucleotide sequence of the complete structural gene encoding Mycoplasma pneumoniae PI cytadhesin and the amino acid sequence of the PI protein is described. The present invention provides recombinant DNA clones encoding the complete PI protein as well as clones expressing PI polypeptides with cytadhesin epitopes. The substantially purified nucleic acid molecular recombinant vectors, recombinant cells, and recombinant polypeptides of the present invention are useful as hybridization probes and immunodiagnostic reagents and may be used to prepare anti-mycoplasmal vaccines.
5026646 BOVINE M O N O C L O N A L ANTIBODIES TO BOVINE HERPESVIRUS ! FROM SEQUENTIAL FUSION HETEROHYBRIDOMAS Randall L Levings, lone R Stoll assigned to The United States of America as represented by the Secretary of Agriculture Stable heterohybridomas which secrete monoclonal antibodies to bovine herpesvirus-1 (BHVI) are obtained by fusing primed bovine
TREATMENT OF HUMAN RETROVIRAL INFECTIONS WITH 2',3'-DIDEOXYINOSINE ALONE A N D IN C O M B I N A T I O N W I T H OTHER ANTIVIRAL COMPOUNDS Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder assigned to The United States of America as represented by the Department of Health and Human Services A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeliciency virus (HIV) infection, with 2'.3"dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2". 3"dideoxyinosine to minimize certain side effects.
5028421 M E T H O D OF TREATING BIRDS Tommy L Fredericksen, James P Thaxton assigned to Embrex Inc A method of treating birds by administering birds in ovo a T-cell growth factor comprising avian IL-2 is disclosed. The method is preferably carried out on chickens with 30K chicken IL-2 on about the eighteenth day of incubation. The method may be employed to increase the weight of treated birds after hatch. A vaccine may optionally be administered concurrently with the avian 1L-2.